{
    "startDate": "2020-01-01",
    "endDate": "2020-09-30",
    "year": "2020",
    "quarter": "Q3",
    "symbol": "TMBR",
    "data": {
        "bs": [
            {
                "label": "Lease liability",
                "concept": "OperatingLeaseLiabilityNoncurrent",
                "unit": "usd",
                "value": 636946
            },
            {
                "label": "Accounts payable",
                "concept": "AccountsPayableCurrent",
                "unit": "usd",
                "value": 566095
            },
            {
                "label": "Cash",
                "concept": "CashAndCashEquivalentsAtCarryingValue",
                "unit": "usd",
                "value": 12033746
            },
            {
                "label": "Notes payable",
                "concept": "LongTermNotesPayable",
                "unit": "usd",
                "value": 37772
            },
            {
                "label": "Lease liability, current portion",
                "concept": "OperatingLeaseLiabilityCurrent",
                "unit": "usd",
                "value": 207275
            },
            {
                "label": "Total members' and stockholders' deficit",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": -1044040
            },
            {
                "label": "Total members' and stockholders' deficit",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": -1044040
            },
            {
                "label": "Total members' and stockholders' deficit",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": -1044040
            },
            {
                "label": "Total assets",
                "concept": "Assets",
                "unit": "usd",
                "value": 13240329
            },
            {
                "label": "Common stock",
                "concept": "CommonStockValue",
                "unit": "usd",
                "value": 11849
            },
            {
                "label": "Commitments and contingencies (Note 11)",
                "concept": "CommitmentsAndContingencies",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Other liabilities",
                "concept": "OtherLiabilitiesNoncurrent",
                "unit": "usd",
                "value": 73683
            },
            {
                "label": "Accumulated deficit",
                "concept": "RetainedEarningsAccumulatedDeficit",
                "unit": "usd",
                "value": -19055496
            },
            {
                "label": "Additional paid-in capital",
                "concept": "AdditionalPaidInCapital",
                "unit": "usd",
                "value": 17999607
            },
            {
                "label": "Other current assets",
                "concept": "OtherAssetsCurrent",
                "unit": "usd",
                "value": 253356
            },
            {
                "label": "Total liabilities and members' and stockholders' deficit",
                "concept": "LiabilitiesAndStockholdersEquity",
                "unit": "usd",
                "value": 13240329
            },
            {
                "label": "Total liabilities",
                "concept": "Liabilities",
                "unit": "usd",
                "value": 12465081
            },
            {
                "label": "Deposits",
                "concept": "DepositsAssetsNoncurrent",
                "unit": "usd",
                "value": 114534
            },
            {
                "label": "Right of use asset",
                "concept": "OperatingLeaseRightOfUseAsset",
                "unit": "usd",
                "value": 838693
            },
            {
                "label": "Total current liabilities",
                "concept": "LiabilitiesCurrent",
                "unit": "usd",
                "value": 11716680
            },
            {
                "label": "Warrant liability",
                "concept": "WarrantsAndRightsOutstanding",
                "unit": "usd",
                "value": 10413855
            },
            {
                "label": "Accrued expenses",
                "concept": "AccruedLiabilitiesCurrent",
                "unit": "usd",
                "value": 529455
            },
            {
                "label": "Total current assets",
                "concept": "AssetsCurrent",
                "unit": "usd",
                "value": 12287102
            }
        ],
        "cf": [
            {
                "label": "Amortization of loan discount",
                "concept": "tmbr:AmortizationOfLoanDiscount",
                "unit": "usd",
                "value": -775000
            },
            {
                "label": "Amortization of debt discount",
                "concept": "AmortizationOfDebtDiscountPremium",
                "unit": "usd",
                "value": 4232718
            },
            {
                "label": "Lease liability",
                "concept": "tmbr:IncreaseDecreaseInOperatingLeaseLiabilities",
                "unit": "usd",
                "value": -61531
            },
            {
                "label": "Net cash provided by financing activities",
                "concept": "NetCashProvidedByUsedInFinancingActivities",
                "unit": "usd",
                "value": 21237778
            },
            {
                "label": "Conversion of common units to common stock pursuant to BioPharmX acquisition",
                "concept": "tmbr:ConversionOfCommonUnitsToCommonStockValue",
                "unit": "usd",
                "value": 74667
            },
            {
                "label": "Net increase in cash and cash equivalents",
                "concept": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
                "unit": "usd",
                "value": 11976679
            },
            {
                "label": "Reclassification of bridge warrant",
                "concept": "tmbr:ReclassificationOfWarrantLiability",
                "unit": "usd",
                "value": 3423204
            },
            {
                "label": "Reclassification of bridge warrant",
                "concept": "tmbr:ReclassificationOfWarrantLiability",
                "unit": "usd",
                "value": 3423204
            },
            {
                "label": "Change in fair value of investment in BioPharmX",
                "concept": "UnrealizedGainLossOnInvestments",
                "unit": "usd",
                "value": 559805
            },
            {
                "label": "Change in fair value of investment in BioPharmX",
                "concept": "UnrealizedGainLossOnInvestments",
                "unit": "usd",
                "value": 559805
            },
            {
                "label": "Accrued interest on BioPharmX loan",
                "concept": "tmbr:IncreaseDecreaseInInterestPayableOnBiopharmxLoan",
                "unit": "usd",
                "value": -41655
            },
            {
                "label": "Purchase of research and development licenses - AFT Pharmaceuticals Limited",
                "concept": "PaymentsToAcquireOtherProductiveAssets",
                "unit": "usd",
                "value": 750000
            },
            {
                "label": "Research and development-licenses acquired",
                "concept": "tmbr:ResearchAndDevelopmentLicenseAcquired",
                "unit": "usd",
                "value": 12371332
            },
            {
                "label": "Research and development-licenses acquired",
                "concept": "tmbr:ResearchAndDevelopmentLicenseAcquired",
                "unit": "usd",
                "value": 12371332
            },
            {
                "label": "Proceeds from the issuance of common stock and warrants, net of issuance costs",
                "concept": "ProceedsFromIssuanceOfCommonStock",
                "unit": "usd",
                "value": 17500006
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -15927714
            },
            {
                "label": "Change in fair value of warrant liability",
                "concept": "FairValueAdjustmentOfWarrants",
                "unit": "usd",
                "value": -5607293
            },
            {
                "label": "Change in fair value of warrant liability",
                "concept": "FairValueAdjustmentOfWarrants",
                "unit": "usd",
                "value": -5607293
            },
            {
                "label": "Amortization of right of use assets",
                "concept": "FinanceLeaseRightOfUseAssetAmortization",
                "unit": "usd",
                "value": 65677
            },
            {
                "label": "Conversion of preferred units to Series A preferred stock pursuant to BioPharmX acquisition",
                "concept": "tmbr:ConversionOfPreferredUnitsToSeriesPreferredStockValue",
                "unit": "usd",
                "value": -1819289
            },
            {
                "label": "Conversion of preferred units to Series A preferred stock pursuant to BioPharmX acquisition",
                "concept": "tmbr:ConversionOfPreferredUnitsToSeriesPreferredStockValue",
                "unit": "usd",
                "value": -1819289
            },
            {
                "label": "Accrued expenses",
                "concept": "IncreaseDecreaseInAccruedLiabilities",
                "unit": "usd",
                "value": -17537
            },
            {
                "label": "Accounts payable",
                "concept": "IncreaseDecreaseInAccountsPayableTrade",
                "unit": "usd",
                "value": -545480
            },
            {
                "label": "Net cash used in operating activities",
                "concept": "NetCashProvidedByUsedInOperatingActivities",
                "unit": "usd",
                "value": -6601885
            },
            {
                "label": "Loan to BioPharmX",
                "concept": "tmbr:LoanToBiopharamx",
                "unit": "usd",
                "value": -2250000
            },
            {
                "label": "Bridge loan converted to equity",
                "concept": "tmbr:ReclassificationOfBridgeLoan",
                "unit": "usd",
                "value": 5000000
            },
            {
                "label": "Bridge loan converted to equity",
                "concept": "tmbr:ReclassificationOfBridgeLoan",
                "unit": "usd",
                "value": 5000000
            },
            {
                "label": "Stock-based compensation",
                "concept": "ShareBasedCompensation",
                "unit": "usd",
                "value": 157187
            },
            {
                "label": "Net cash used in investing activities",
                "concept": "NetCashProvidedByUsedInInvestingActivities",
                "unit": "usd",
                "value": -2659214
            },
            {
                "label": "Series A liability classified warrants",
                "concept": "StockIssued1",
                "unit": "usd",
                "value": 16511634
            },
            {
                "label": "Issuance of common stock for acquisition of BioPharmx",
                "concept": "tmbr:NoncashFinancingTransactionsConversionOfWarrantsCommonStockLiability",
                "unit": "usd",
                "value": 8368026
            },
            {
                "label": "Other current assets",
                "concept": "IncreaseDecreaseInOtherCurrentAssets",
                "unit": "usd",
                "value": 218509
            },
            {
                "label": "Proceeds from bridge notes payable",
                "concept": "tmbr:ProceedsFromBridgeNotesPayable",
                "unit": "usd",
                "value": 3700000
            },
            {
                "label": "Accrued interest on bridge notes",
                "concept": "tmbr:IncreaseDecreaseInInterestPayableOnBridgeNotes",
                "unit": "usd",
                "value": 183333
            },
            {
                "label": "Cash acquired with acquisition of BioPharmX",
                "concept": "CashAcquiredFromAcquisition",
                "unit": "usd",
                "value": 340786
            },
            {
                "label": "Non-cash contribution from TardiMed",
                "concept": "tmbr:NonCashContributionFromTardimed",
                "unit": "usd",
                "value": 142392
            },
            {
                "label": "Non-cash contribution from TardiMed",
                "concept": "tmbr:NonCashContributionFromTardimed",
                "unit": "usd",
                "value": 142392
            },
            {
                "label": "Proceeds from PPP loan",
                "concept": "ProceedsFromRepaymentsOfDebt",
                "unit": "usd",
                "value": 37772
            }
        ],
        "ic": [
            {
                "label": "Change in fair value of warrant liability",
                "concept": "FairValueAdjustmentOfWarrants",
                "unit": "usd",
                "value": -5607293
            },
            {
                "label": "Change in fair value of warrant liability",
                "concept": "FairValueAdjustmentOfWarrants",
                "unit": "usd",
                "value": -5607293
            },
            {
                "label": "Gain on foreign currency exchange",
                "concept": "ForeignCurrencyTransactionGainLossBeforeTax",
                "unit": "usd",
                "value": 11651
            },
            {
                "label": "Diluted weighted average number of shares outstanding",
                "concept": "WeightedAverageNumberOfDilutedSharesOutstanding",
                "unit": "shares",
                "value": 12161048
            },
            {
                "label": "Loss from operations",
                "concept": "OperatingIncomeLoss",
                "unit": "usd",
                "value": -18506372
            },
            {
                "label": "Net income (loss) attributable to common stockholders",
                "concept": "NetIncomeLossAvailableToCommonStockholdersBasic",
                "unit": "usd",
                "value": -16034214
            },
            {
                "label": "Total operating expenses",
                "concept": "OperatingExpenses",
                "unit": "usd",
                "value": 18857800
            },
            {
                "label": "Transaction costs",
                "concept": "tmbr:TransactionCosts",
                "unit": "usd",
                "value": 1501133
            },
            {
                "label": "Diluted net income (loss) per share attributable to common stockholders",
                "concept": "EarningsPerShareDiluted",
                "unit": "usd/shares",
                "value": -1.32
            },
            {
                "label": "Basic net income (loss) per share attributable to common stockholders",
                "concept": "EarningsPerShareBasic",
                "unit": "usd/shares",
                "value": -1.32
            },
            {
                "label": "Interest income",
                "concept": "OtherNonoperatingIncome",
                "unit": "usd",
                "value": 816655
            },
            {
                "label": "Net income (loss)",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": -15927714
            },
            {
                "label": "Net income (loss)",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": -15927714
            },
            {
                "label": "Change in fair value of investment in BioPharmX",
                "concept": "UnrealizedGainLossOnInvestments",
                "unit": "usd",
                "value": 559805
            },
            {
                "label": "Change in fair value of investment in BioPharmX",
                "concept": "UnrealizedGainLossOnInvestments",
                "unit": "usd",
                "value": 559805
            },
            {
                "label": "Grant revenues",
                "concept": "RevenueFromContractWithCustomerIncludingAssessedTax",
                "unit": "usd",
                "value": 351428
            },
            {
                "label": "Interest expense",
                "concept": "OtherNonoperatingExpense",
                "unit": "usd",
                "value": 4416746
            },
            {
                "label": "Research and development",
                "concept": "ResearchAndDevelopmentExpense",
                "unit": "usd",
                "value": 2239607
            },
            {
                "label": "Cumulative dividends on Series A preferred stock",
                "concept": "tmbr:CumulativeDividendsOnSeriesPreferredStockIncomeStatementImpact",
                "unit": "usd",
                "value": 53831
            },
            {
                "label": "Basic weighted average number of shares outstanding",
                "concept": "WeightedAverageNumberOfSharesOutstandingBasic",
                "unit": "shares",
                "value": 12161048
            },
            {
                "label": "Research and development - license acquired",
                "concept": "tmbr:ResearchAndDevelopmentLicenseAcquired",
                "unit": "usd",
                "value": 12371332
            },
            {
                "label": "Research and development - license acquired",
                "concept": "tmbr:ResearchAndDevelopmentLicenseAcquired",
                "unit": "usd",
                "value": 12371332
            },
            {
                "label": "Selling, general and administrative",
                "concept": "SellingGeneralAndAdministrativeExpense",
                "unit": "usd",
                "value": 2745728
            },
            {
                "label": "Total other income",
                "concept": "NonoperatingIncomeExpense",
                "unit": "usd",
                "value": 2578658
            },
            {
                "label": "Accrued dividend on preferred stock units",
                "concept": "PreferredStockDividendsIncomeStatementImpact",
                "unit": "usd",
                "value": 52669
            }
        ]
    }
}